ABSTRACT
In this study, our goal is to identify potentially vulnerable communities that could be subject to ongoing or compounding impacts from the pandemic and/or that may experience a slower recovery due to sociodemographic factors. For this purpose, we compiled information from multiple databases related to sociodemographic and health variables. We used a ranking-based method to integrate them and develop new combined indices. We also investigated a time-dependent correlation between vulnerability components and COVID-19 statistics to understand their time-dependent relationship. We ultimately developed pandemic vulnerability indices by combining CDC's social vulnerability index, our newly developed composite health vulnerability index, and COVID-19 impact indices. We also considered additional assessments include expected annual loss due to natural hazards and community resilience. Potential hot spots (at the county level) were identified throughout the United States, and some general trends were noted. Counties with high COVID-19 impact indices and higher values of the pandemic vulnerability indices were primarily located in the southern United States or coastal areas in the Eastern and Southwestern United States at the beginning of the COVID-19 pandemic. Over time, the computed pandemic vulnerability indices shifted to higher values for counties in the southern and north-central United States, while values calculated for the northwestern and northeastern communities tended to decrease.
ABSTRACT
In this study, our goal is to identify potentially vulnerable communities that could be subject to ongoing or compounding impacts from the pandemic and/or that may experience a slower recovery due to sociodemographic factors. For this purpose, we compiled information from multiple databases related to sociodemographic and health variables. We used a ranking-based method to integrate them and develop new combined indices. We also investigated a time-dependent correlation between vulnerability components and COVID-19 statistics to understand their time-dependent relationship. We ultimately developed pandemic vulnerability indices by combining CDC's social vulnerability index, our newly developed composite health vulnerability index, and COVID-19 impact indices. We also considered additional assessments include expected annual loss due to natural hazards and community resilience. Potential hot spots (at the county level) were identified throughout the United States, and some general trends were noted. Counties with high COVID-19 impact indices and higher values of the pandemic vulnerability indices were primarily located in the southern United States or coastal areas in the Eastern and Southwestern United States at the beginning of the COVID-19 pandemic. Over time, the computed pandemic vulnerability indices shifted to higher values for counties in the southern and north-central United States, while values calculated for the northwestern and northeastern communities tended to decrease.
ABSTRACT
The ongoing pandemic illustrates limited therapeutic options for controlling SARS-CoV-2 infections, calling a need for additional therapeutic targets. The viral spike S glycoprotein binds to the human receptor angiotensin-converting enzyme 2 (ACE2) and then is activated by the host proteases. Based on the accessibility of the cellular proteases needed for SARS-S activation, SARS-CoV-2 entrance and activation can be mediated by endosomal (such as cathepsin L) and non-endosomal pathways. Evidence indicates that in the non-endosomal pathway, the viral S protein is cleaved by the furin enzyme in infected host cells. To help the virus enter efficiently, the S protein is further activated by the serine protease 2 (TMPRSS2), provided that the S has been cleaved by furin previously. In this review, important roles for host proteases within host cells will be outlined in SARS-CoV-2 infection and antiviral therapeutic strategies will be highlighted. Although there are at least five highly effective vaccines at this time, the appearance of the new viral mutations demands the development of therapeutic agents. Targeted inhibition of host proteases can be used as a therapeutic approach for viral infection.